Xtl生物制药 XTLB 深 沪
已收盘 07-02 16:00:00 美东时间
2.70
+0.210
+8.43%
华盛通- 最 高2.74
- 今 开2.44
- 成交量 4.74万股
- 最 低 2.36
- 昨 收 2.49
- 总市值 638.71万
- 52周最高 10.2796
- 市盈率 静 --
- 换手率 2.00%
- 52周最低 2.0101
- 委 比 -88.24%
- 总股本 236.56万
- 历史最高 151.00
- 量 比 0.06
- 振 幅 15.26%
- 历史最低 2.1204
- 每 手 1
- 风险率 1.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多XTL Biopharmaceuticals Completes Psyga Bio Acquisition, Refocuses on Psychedelic Medicine
The latest update is out from XTL Biopharmaceuticals Sponsored ADR ( ($XTLB) )....
07-01 05:48
XTL Completed the Acquisition of Psyga Bio Ltd.
XTL Biopharmaceuticals completes acquisition of Psyga Bio, becoming a dedicated psychedelic medicine company. The deal positions XTL with a clinical pipeline, GMP manufacturing facility, and IP library. Psyga Bio's products target severe mental health disorders. The acquisition was approved by regulators and supported by $1.5M in funding. The U.S. regulatory environment is favorable, with the FDA accelerating approvals for psychedelic treatments....
06-30 21:15
XTL Receives Nasdaq Noncompliance Letter
Nasdaq informed the Company that this matter serves as an additional basis for delisting the Company's securities from Nasdaq and that the Nasdaq Hearings Panel (the "Panel") will consider this matter in its decision
05-23 04:12
XTL Announces Receipt of Staff Delist Determination from Nasdaq
XTL Biopharmaceuticals Ltd. received a notice from Nasdaq regarding its failure to file the 2025 Annual Report on Form 20-F, violating Listing Rule 5250(c)(1). This adds to existing delisting issues related to insufficient stockholders' equity and bid price. The company may present its case to the Nasdaq Hearings Panel by May 26, 2026, and has requested an extended stay of securities suspension. Continued listing is not assured. XTL focuses on st...
05-22 20:10
XTL Biopharmaceuticals Signs Agreement To Acquire Psyga Bio; Financial Terms Undisclosed
XTL Biopharmaceuticals Ltd. (the "Company" or "XTL") announced today that it has entered into a definitive share purchase agreement (the "Purchase Agreement") to acquire 100% of the issued and outstanding share capital
04-29 21:01
XTL Biopharmaceuticals announces 1-for-4 ADS ratio change
XTL Biopharmaceuticals (XTLB) will change its ADS ratio from 1:100 to 1:400 effective March 25, 2026. The move is equivalent to a 1-for-4 reverse ADS split for shareholders. No fractional ADSs will be...
03-21 04:19
XTL Biopharma To Implement 1-For-4 Reverse ADS Split, Effective March 25, 2026
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares, par
03-21 04:10
XTL Biopharmaceuticals Announces ADS Ratio Change
XTL Biopharmaceuticals Ltd. announced plans to change its American Depositary Shares (ADS) ratio from 1 ADS to 100 ordinary shares to 1 ADS to 400 ordinary shares, effective March 25, 2026. This change is equivalent to a 1-for-4 reverse ADS split. ADS holders will receive 1 new ADS for every 4 existing ADSs, with no fees charged. Fractional ADSs will be sold and proceeds distributed to holders. The company expects its ADS trading price to increas...
03-20 20:10
Beyond Air halts sale of NeuroNOS subsidiary to XTL Biopharmaceuticals
Beyond Air (XAIR) has terminated an agreement with XTL Biopharmaceuticals to sell its majority ownership interest in NeuroNOS subsidiary The companies had entered into a letter of intent in January ...
03-10 19:59
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
Beyond Air, Inc. has terminated its proposed transaction with XTL Biopharmaceuticals Ltd. regarding its NeuroNOS subsidiary. The letter of intent expired on March 9, 2026, and no definitive agreement was reached. Beyond Air remains committed to maximizing the value of NeuroNOS and advancing its core nitric oxide platform and LungFit programs.
03-10 11:30
